Financial Data and Key Metrics Changes - The company ended 2025 with $245.8 million in cash and investments and no debt on its balance sheet [16][41] - Revenue for Q4 2025 was $21.8 million, with a full-year revenue of $55.2 million [43] - R&D expenses for Q4 2025 were $29.7 million, totaling $117.3 million for the full year [43] - G&A expenses for Q4 2025 were $11.2 million, with a full-year total of $68.7 million [43] - The net loss for Q4 2025 was $36.1 million, or $1.78 per share, while the full-year net loss was $164.1 million, or $9.73 per share [43][44] Business Line Data and Key Metrics Changes - The company is focusing on advancing its immunology and inflammation pipeline, particularly the Treg biologic, rezpegaldesleukin [6][7] - Positive results were achieved in phase 2b studies for atopic dermatitis and alopecia areata, validating the Treg mechanism [8][10] - The atopic dermatitis market is projected to grow to approximately $35 billion by the mid-2030s, with significant unmet needs in treatment [11][12] Market Data and Key Metrics Changes - In the U.S., over 15 million people suffer from moderate to severe atopic dermatitis, with only 10%-15% currently receiving biologic treatments [10] - Approximately 50% of patients fail to respond or lose treatment effect over time with current IL-13-based therapies, indicating a significant opportunity for REZPEG [11][12] Company Strategy and Development Direction - The company plans to initiate phase 3 studies for REZPEG in June 2026, with a goal to submit a BLA in 2029 [15][16] - The competitive landscape for late-stage novel mechanisms of action (MOAs) has narrowed, positioning REZPEG favorably [12] - The company aims to leverage its differentiated efficacy and safety profile to capture market share in the atopic dermatitis and alopecia areata markets [12][13] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful outcomes of phase 2 studies and the potential for REZPEG to provide complete disease clearance over time [9][10] - The company expressed confidence in its strong balance sheet, allowing for rapid advancement into phase 3 studies [16][41] - Management noted the importance of achieving a differentiated safety profile compared to existing treatments, particularly JAK inhibitors [13][56] Other Important Information - The company raised approximately $476 million in additional net cash through a public offering and ATM exercises [16][41] - The phase 3 program for REZPEG will evaluate both biologic-naive and treatment-experienced patients [27][61] Q&A Session Summary Question: What type of new data can be expected from the AAD conference presentation? - The upcoming presentation will showcase additional effects of treatment with REZPEG and potential for more patients to achieve SALT 20 responses [49][51] Question: Will ACQ-5 data be included in the phase 3 program? - ACQ-5 will be included in the phase 3 program, and efforts will be made to include it in the label [61] Question: What is the formulation or device for REZPEG being considered? - REZPEG will be launched in an auto-injector device, with weight-banded dosing for ease of administration [71] Question: How many patients completed the extension phase of the alopecia study? - There were 23 patients ongoing in the 16-week extension, and all treatment stops for all patients at either week 36 or week 52 [114] Question: How does REZPEG differentiate from other approaches in type 1 diabetes? - REZPEG offers an outpatient dosing regimen without the need for routine monitoring, contrasting with the IV infusion required for Tzield [108][109]